Mesoblast assumed with a Buy at H.C. Wainwright. H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Mesoblast with a Buy rating and $6.50 price target. The company’s proprietary platform has been validated by two commercial cellular therapy products, TEMCELL and Alofisel, which were approved in Japan in 2015 for the treatment of acute Graft Versus Host Disease, and in Europe in 2018 for the treatment of perianal fistula, Ramakanth tells investors in a research note. Further, he calls Mesoblast’s product pipeline “mature” with seven product candidates targeting ten indications.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.